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Objective: The aim was to investigate whether coffee or caffeine consumption is associated 
with reproductive endpoints among women with natural fertility (ie, time to pregnancy [TTP] 
and spontaneous abortion [SAB]) and among women in fertility treatment (ie, clinical pregnancy 
rate or live birth rate).
Design: This study was a systematic review and dose–response meta-analysis including data 
from case–control and cohort studies. 
Methods: An extensive literature search was conducted in MEDLINE and Embase, with no 
time and language restrictions. Also, reference lists were searched manually. Two independent 
reviewers assessed the manuscript quality using the Newcastle–Ottawa Scale (NOS). A two-
stage dose–response meta-analysis was applied to assess a potential association between coffee/
caffeine consumption and the outcomes: TTP, SAB, clinical pregnancy, and live birth. Hetero-
geneity between studies was assessed using Cochrane Q-test and I2 statistics. Publication bias 
was assessed using Egger’s regression test.
Results: The pooled results showed that coffee/caffeine consumption is associated with a 
significantly increased risk of SAB for 300 mg caffeine/day (relative risk [RR]: 1.37, 95% 
confidence interval [95% CI]: 1.19; 1.57) and for 600 mg caffeine/day (RR: 2.32, 95% CI: 1.62; 
3.31). No association was found between coffee/caffeine consumption and outcomes of fertility 
treatment (based on two studies). No clear association was found between exposure to coffee/
caffeine and natural fertility as measured by fecundability odds ratio (based on three studies) 
or waiting TTP (based on two studies). 
Conclusion: Results from this meta-analysis support the growing evidence of an association 
between coffee/caffeine intake and the risk of SAB. However, viewing the reproductive capac-
ity in a broader perspective, there seems to be little, if any, association between coffee/caffeine 
consumption and fecundity. In general, results from this study are supportive of a precautionary 
principle advised by health organizations such as European Food Safety Authority (EFSA) and 
World Health Organization (WHO), although the advised limit of a maximum of two to three 
cups of coffee/200–300 mg caffeine per day may be too high. 
Keywords: coffee, caffeine, fecundity, fertility, spontaneous abortion, assisted reproduction
Plain language summary 
Coffee and other caffeinated beverages are widely consumed by women desiring to conceive as 
well as pregnant women. Whether such consumption reduces the chance of achieving a preg-
nancy or may have harmful effects on the developing fetus is widely debated. As a contribution 
to this debate and given the growing concern of subfecundity and infertility in public health, 
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we investigated the risk of coffee or caffeine consumption on the 
ability to conceive a pregnancy and to carry the pregnancy to term. 
Results from this study showed an increased risk of experiencing 
a spontaneous abortion with increasing consumption of coffee/
caffeine during early pregnancy. No clear association was found 
between coffee/caffeine consumption and the chance of achieving 
a pregnancy among women/couples trying to conceive naturally 
or by women/couples receiving fertility treatment. Results from 
this study support the precautionary principle advised by health 
organizations such as European Food Safety Authority (EFSA) and 
World Health Organization (WHO), although the advised limit of a 
maximum of two to three cups of coffee/200–300 mg caffeine per 
day may be too high.
Introduction
Subfecundity and infertility are multifactorial conditions 
of growing concern in public health. Worldwide, one in six 
couples experience fecundity problems during their repro-
ductive lifetime.1–3 While the cause often may be explained 
by failure of ovulation, damages on the fallopian tubes, or 
low sperm count, the reduced fecundity is still unexplained 
in many cases. Thus, investigations of a potential effect of 
modifiable exposures on longer waiting time to pregnancy 
(TTP), increased rate of spontaneous abortion (SAB), or 
reduced live birth rate are important.
Coffee consumption is common among people through-
out the world. Worldwide, Finland has the highest consump-
tion (12.0 kg coffee/person/year), with Denmark being the 
fourth most coffee-consuming country (8.7 kg coffee/person/
year). Also, coffee and other caffeine-containing drinks and 
foods are widely consumed by women desiring to conceive 
and by pregnant women. On average, a cup of coffee contains 
~100 mg of caffeine.4 
Even small effects of coffee or caffeine intake on fecun-
dity could have considerable public health consequences, 
considering the large consumption of these substances.
The European Food Safety Authority (EFSA) recommends 
women desiring to conceive and pregnant women to keep 
their daily caffeine consumption below 200 mg,5 while WHO 
recommends a daily caffeine intake below 300 mg.6 Caffeine 
is a central ingredient in coffee, while other sources of caffeine 
include tea, soft drinks, chocolate, and some medications.
The association between caffeine intake and female 
fecundity has been studied with inconsistent findings, in 
studies with both retrospectively7–13 and prospectively col-
lected exposure data.14–19 A high level of coffee consumption 
during pregnancy has been associated with an increased risk 
of fetal death after 20 weeks of gestation20,21 and stillbirth.22 
In meta-analyses, an increased risk of low birth weight and 
small for gestational age was found,23 but no association was 
found between caffeine intake during pregnancy and the risk 
of preterm birth.23,24
Recently, a meta-analysis reported that an increment 
in intake of 100 mg caffeine per day was associated with a 
14% increased risk of SAB.23 However, the authors did not 
account for the varying quality of the included studies, includ-
ing varying (or none) adjustment for potential confounders. 
Studies that fail to adjust for important risk factors associated 
with SAB may over- or underestimate the risk associated 
with caffeine consumption. Hence, taking adjustment status 
into account would considerably improve the quality of a 
meta-analysis. Moreover, other substances in coffee besides 
caffeine might play an important role. Finally, applying a 
broader view on fecundity through inclusion of different 
reproductive endpoints among both women conceiving 
naturally and following fertility treatment could extend the 
use of the results and help general practitioners and fertility 
clinics provide balanced information to women and couples 
seeking advice or even fertility treatment. No meta-analysis 
has previously reported on a possible association between 
coffee/caffeine intake and TTP or endpoints among couples 
in fertility treatment.
The aim of this systematic review and dose-response 
meta-analysis was to investigate whether consumption of 
coffee or caffeine is associated with reproductive endpoints 
among women with natural fertility (ie TTP and SAB) and 
among women in fertility treatment (ie clinical pregnancy 
rate and live birth rate).
Methods
A review protocol is available from the PROSPERO data-
base.25 The protocol was registered on June 9, 2015 (registra-
tion number: CRD42015020333). 
Search strategy and selection
We conducted a comprehensive literature search in MED-
LINE and Embase databases with the help of a medical 
librarian on May 26, 2015. The following keywords and 
medical subject headings were used to identify relevant 
articles in the databases: ([“Fertility” or “Infertility, Female” 
or “Reproduction” or “Preconception Care”) or [“Reproduc-
tive Techniques, Assisted” or “Reproductive Techniques” or 
“fertility treatment”]) AND (“Caffeine/adverse effects” or 
“Coffee”) AND (“Case-Control Studies” or “Cohort Stud-
ies”). To include non-indexed new literature, an additional 
search was performed using free text terms. No restrictions 
were made regarding study language or year of publication. 
Further, the reference lists of retrieved articles and reviews 
were searched manually for additionally relevant studies. The 
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first author reviewed all retrieved articles for eligibility by 
title and abstract by consulting with at least one co-author in 
cases of any doubt about the inclusion of a given study or not. 
Potentially eligible articles were thoroughly read in full text to 
check whether they fulfilled the following inclusion criteria: 
1. Participants had to be either women/couples trying to 
conceive naturally or women/couples trying to conceive 
by medically assisted reproduction (MAR) treatment
2. Studies that reported a numerical exposure range of either 
coffee or caffeine consumption 
3. Studies that investigated at least one of the outcomes of 
interest: TTP, SAB, clinical pregnancy, and live birth
4. Articles that reported data from original studies (ie, no 
review articles)
5. Studies of which the design was a case-control study or 
a cohort study (ie, no RCT)
Before finalizing the manuscript, the database search was 
repeated on April 3, 2017. 
Data extraction 
All included full text articles were read independently by at 
least two authors. A data extraction form was developed a 
priori, ensuring a standardized procedure. The following data 
were extracted: lead author surname, study title, country of 
origin, year of publication and journal, study design, study 
population (size and selection), exposure and outcome assess-
ment, covariates adjusted for, main results, study limitations, 
and assessment of quality scoring. 
We assessed the quality of all included studies using the 
Newcastle–Ottawa Scale (NOS).26 Thus, the selection process 
and comparability of the study groups as well as the ascertain-
ment of exposure or outcome of interest of the included stud-
ies were evaluated for either cohort or case–control studies 
(please see scoring details in the Supplementary material). In 
addition to the NOS scheme, we constructed an explanatory 
form ensuring a standardized scoring among the authors with 
regard to the specific scope of this review (Supplementary 
material). When using NOS to evaluate study comparability, 
one has to choose the two most important covariates. Hence, 
based on the current knowledge, maternal age was chosen 
as the most important factor to adjust for. As additionally 
important adjustment factors, smoking was chosen for 
studies evaluating TTP and MAR treatment, while maternal 
alcohol consumption was chosen for those investigating 
SAB. All studies were allocated a total score between 0 and 
9 independently by a minimum of two authors. Any incon-
sistency was resolved by discussion, leading to a uniform 
decision. Studies with a total score of ≥7 were considered 
as “ high-quality studies”, and in a sub-analysis, studies were 
stratified according to this selected cut-off value. Regardless 
of total NOS score, all studies were included in the review.
This review is reported in accordance with the PRISMA 
statement27 for reporting of systematic review and meta-
analysis. Supplementary material regarding the full search 
strategy for MEDLINE, elaborated reasons for exclusion, and 
NOS explanatory form are all available online. 
Outcomes
The ability to naturally conceive was investigated by two 
broad fecundability measures including TTP (ie, the number 
of months or cycles taken by a couple to conceive, when 
being sexually active and not using birth control) and fecund-
ability odds ratio (FOR) (ie, the ratio of couple’s probability 
of conceiving in one menstrual cycle).28 The capability of 
maintaining a pregnancy after conception was evaluated by 
the risk of experiencing an SAB (yes/no). Among couples 
receiving MAR treatment, a possible association was inves-
tigated using different endpoints to evaluate a successful 
fertility treatment (ie, achieving a pregnancy or live birth 
after fertility treatment; yes/no). 
Statistical analysis 
Although still included in the review, studies were excluded 
from the meta-analyses if they did not provide information on 
the number of cases and total number of subjects within each 
exposure category and whose corresponding author did not 
respond to emails asking for additional data to calculate these 
numbers.7,9,10,14,15,17,29–33 Also, we excluded studies that did not 
report on three or more quantitative categories of coffee/caf-
feine consumption,34–37 as these cannot contribute sufficient 
data when performing a dose–response meta-analysis.38
We applied a two-stage dose–response meta-analysis 
to assess a potential association between coffee/caffeine 
consumption and our outcomes.39 For fecundability and 
MAR treatment, we included only fixed effects in the meta-
analysis due to the low number of included studies,40 while 
for SAB, we conducted a random-effects meta-analysis after 
considering heterogeneity between studies. As coffee/caffeine 
consumption was reported on various scales, we converted 
exposure data into a uniform measurement (mg/day). Studies 
reporting consumption in cups of coffee were recalculated 
into an approximate caffeine content, assuming that one 
cup of coffee in general contains 100 mg caffeine.4,41 As the 
approximation of caffeine content per cup of coffee might 
be imprecise, a sensitivity analysis was performed, assuming 
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that one cup of coffee contained 150 mg caffeine. Coffee/
caffeine consumption was modeled using restricted cubic 
splines with three knots at the 10th, 50th, and 90th percentiles 
of the distribution of doses.38,42,43 For each model, we present 
an overall p-value testing that the two regression coefficients 
describing the nonlinear relationship were simultaneously 
equal to zero. Also, upon finding a statistical significant 
association, we present a p-value testing the linear versus 
nonlinear relationship.44 When analyzing risk of SAB, we 
performed stratified analyses by type of consumption (caf-
feine vs coffee), adjustment status (crude vs any adjustment), 
study quality (NOS>7 vs NOS<7), and study design (cohort 
vs case–control). Similar analyses were not possible for other 
outcomes due to the low number of studies. Heterogeneity 
between studies was assessed using the Cochrane Q-test and 
the I2 statistic. Low heterogeneity was defined by I2 values 
<25%, while a I2 value >75% was considered an indicator of 
substantial heterogeneity.45 Publication bias was assessed for 
SAB studies, using Egger’s regression test.46 As meta-analysis 
for fecundity and MAR endpoints only included a maximum 
of three studies, tests of heterogeneity and publication bias 
were irrelevant for these outcomes.47 All statistical analyses 
were performed using the “dosresmeta” and “metafor” pack-
ages in R version 3.3.1.48,49 p-values <0.05 were considered 
statistically significant.
Results
Characteristics of the included studies
A total number of 379 articles were identified through the 
systematic literature search, and an additional 68 articles 
were identified through a manual search of their references 
( Figure 1). Of the total 447 articles, 136 were duplicates 
and thus excluded. The remaining 311 unique articles were 
screened by title and, if necessary, by abstract, and 195 did 
not meet the eligibility criteria. Full-texts were assessed 
for the remaining 116 articles. Of these, 68 articles were 
excluded due to not meeting the eligibility criteria, and 
one article was excluded due to insufficient data reporting. 
Thus, a total of 47 studies were included in the systematic 
review. Of these, 35 studies had dose–response information 
(ie, reporting at least three or more quantitative exposure 
categories) and were included in our meta-analyses. Of 
these 35 studies, 5 studies reported about the endpoints of 
fecundity9,10,16,19,50, 27 studies reported about SAB,21,32,34,51–73 
and 3 studies reported on the outcomes of MAR.74–76 Results 
from the remaining 12 studies that did not provide sufficient 
data to be included in the meta-analysis are included as a 
narrative description. 
All included studies were published between 1988 
and 2015. Thirty-one were cohort studies, while 16 were 
case–control studies. Study characteristics, results, and the 
assigned total NOS scores are presented in Tables 1–3 (for 
NOS elaborations, please see the Table S1). The presented 
results cover a variety of countries with large differences in 
exposure levels ranging from non-consumers to those who 
consume over 1,200 mg/day (corresponding to 12 cups of cof-
fee/day). Also, adjustment for potential confounders varied 
considerably between studies (Tables 1–3). 
FOR
In the three cohort studies providing sufficient data to be 
included in the meta-analysis, we found no indication of an 
association between caffeine intake up to 400 mg/day and 
altered FOR (overall p=0.76; Figure 2A). Compared with 
no caffeine intake, the pooled odds ratios for altered fecund-
ability were 1.03 (95% confidence interval [CI]: 0.83; 1.28) 
for 100 mg caffeine/day and 1.09 (95% CI: 0.86; 1.37) for 
400 mg caffeine/day. 
Studies not eligible for meta-analysis 
Five other studies have addressed a possible association 
between coffee/caffeine consumption and fecundability with 
contradicting findings. Two studies from the US13,15 includ-
ing a total of 104 and 6,303 women, respectively reported 
reduced fecundability with higher caffeine consumption in 
the late 1980s. However, results by three later studies (two 
European studies and one US study)14,17,30 including 259 and 
423, and 470 women, respectively, support the findings of no 
association between caffeine consumption on fecundability. 
TTP
Only two cohort studies provided sufficient data on TTP, to 
be included in the dose–response meta-analysis. The results 
did not indicate an association (p=0.43 for TTP >6 months 
and p=0.98 for TTP >12 months) (Figure 2B and 2C). 
Compared with no caffeine intake, the pooled relative 
risks for TTP >6 months were 0.92 (95% CI: 0.79; 1.07) for 
100 mg caffeine/day and 0.76 (95% CI: 0.49; 1.18) for 600 
mg caffeine/day. For TTP >12 months, the pooled relative 
risks were 0.99 (95% CI: 0.88; 1.11) for 100 mg caffeine/
day and 0.97 (95% CI: 0.71; 1.33) for 600 mg caffeine/day, 
compared with no caffeine intake. 
Studies not eligible for meta-analysis 
Two studies that were not included in the meta-analysis 
have investigated a possible association between caffeine 
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consumption and TTP. Bolúmar et al7 reported on 3,146 
European women and found an increased risk of TTP >9.5 
months with a caffeine intake of >500 mg/day when reporting 
retrospectively on their first pregnancy. However, no associa-
tion was found when reporting on the most recent waiting 
time. Another study including 66 American women29 did not 
find an association between caffeine consumption and TTP. 
SAB
We found that higher intake of caffeine was associated with 
higher risk of spontaneous abortion (overall association 
p<0.0001; p for non-linearity <0.01), based on 27 studies 
providing sufficient data to be included in the meta-analysis 
(Figure 2D). Compared with no caffeine intake, the pooled 
relative risks for SAB were 1.08 (95% CI: 1.03; 1.13) for 
Figure 1 Flow diagram.
Abbreviations: SAB, spontaneous abortion; MAR, medically assisted reproduction.
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Table 1 Characteristics and results of publications on coffee/caffeine and fecundity endpoints
Author and 
year
Country Design Study groups
included in the analyses
Source of 
caffeine
Controls for 
maternal age
Controls 
for other 
important 
covariates
Confounding factors Main results Total NOS 
score
wilcox et al, 
198815
US Cohort N=104 volunteering healthy women who did not 
become pregnant in the first 3 months of trying to 
conceive
Multiple Yes Yes Age, frequency of intercourse, age at menarche, 
woman’s prenatal exposure to mother’s smoking. 
Subanalysis resticted to non-smokers 
women with a caffeine intake had a decreased fecundability
FOR: 0.51 (95% Ci 0.35; 0.75)
6
Christianson et al, 
198913
US Cohort N=6,303 pregnant women Coffee No Yes Ethnicity, parity, smoking women with a coffee intake of >7 cups/day had an increased 
risk of experiencing difficulties in becoming pregnant 
RR: 1.96*
4
Olsen, 19919 Denmark Cohort N=5,309 non-smoking pregnant Danish women who 
had reached their 3rd trimester
Cases: 523
Multiple Yes Yes Main analysis – data stratified on smoking status.
Adjusted for number of pregnancies, father’s age, 
mother’s and father’s alcohol drinking habits, shift 
work, mother’s education, mother’s and father’s 
smoking habits
Among nonsmokers, there was no association between 
coffee/tea intake >8 cups/day and TTP >6 or TTP >12 
months 
OR: 0.92 (95% Ci 0.71; 1.19) and OR: 0.98 (95% Ci 0.70; 1.37) 
Among smokers, an intake of >8 cups/day was associated 
with TTP >12 months
OR: 1.35 (95% Ci 1.02; 1.48)
6
Florack et al, 
199417
The 
Netherlands
Cohort N=259
Dutch women planning a pregnancy within a year, 
hospital workers 
Coffee No No Main analysis = crude analysis.
Subanalysis: controling for smoking and partners 
behavioral risk factors
women with a caffeine intake of 400–700 mg/day had an 
increased fecundability 
FOR: 2.10 (95% Ci 1.20; 3.70)
7
Alderete et al, 
199510
US Cohort N=787
Primigravidas and married American women 
Coffee Yes Yes Stratification by smoking status.
Adjusted for age, race, BMi, education, prior use of 
contraceptive pills, alcohol consumption, husband’s 
smoking habits, income, whether pregnancy was 
planned, abnormal reproductive conditions, immune 
and endocrine disorders
Nonsmoking women with a coffee intake >3 cups/day had no 
increased risk of TTP >3 months (187 cases)
OR: 1.10 (95% Ci 0.70; 1.80)
TTP >6 months (104 cases)
OR: 1.00 (95% Ci 0.60; 1.80) or TTP >12 months (56 cases)
OR: 1.00 (95% Ci 0.50; 1.70)
7
Bolúmar et al, 
19977 
Spain Cohort N=3,146
European women in the fertile age, planning their first 
pregnancy 
Multiple Yes Yes Age, parity, smoking, alcohol consumption, 
frequency of intercourse, educational level, working 
status, use of oral contraceptives, and country
Women with a caffeine intake during the first pregnancy of 
>500 mg/day had an increased risk of TTP >9.5 months
OR: 1.45 (95% Ci 1.03; 2.04)
No association between total caffeine intake >500 mg/day or 
coffee intake >5 cups/day and TTP >9.5 months (N=3.053)
OR: 1.32 (95% Ci 0.94; 1.86) and OR: 1.26 (95% Ci 0.91; 
1.74) during the most recent waiting time 
6
Caan et al, 199816 US Cohort N=187 volunteering American women, pregnancy 
planners who had been trying for 3 months or less to 
conceive
in total 737 cycles; 115 pregnant cycles and 622 non-
pregnant cycles 
Multiple/
coffee
Yes Yes Age, BMi, gravidity, frequency of intercourse, 
smoking, and alcoholic beverage
No risk of reduced fecundability with total caffeine intake 
>106.8 mg/day 
OR: 1.09 (95% Ci 0.63; 1.89)
or coffee intake >1 cup/day 
OR: 0.77 (95% Ci 0.43; 1.37)
6
Hakim et al, 
199819
US Cohort N=98 volunteering American women in the 
reproductive age, employed at two semiconductor 
plants
No. of conceptions: 90 
No. of menstrual cycles: 536 
Coffee Yes Yes Participants’ age, number of occurrences of sexual 
intercourse in each month, alcohol consumption.
The analysis was restricted to nonsmoking women
Nonsmoking women had no risk of reduced fecundability 
with caffeine intake >300 mg/day 
OR: 0.83 (95% Ci 0.34; 2.01)
7
Jensen et al, 
199814
Denmark Cohort N=423 volunteering Danish couples, nulliparous and 
pregnancy planners with 1,596 cycles 
Multiple/
coffee
No Yes Stratification by smoking.
Total caffeine adjusted for female BMi, alcohol 
intake, deseases of the reproductive organs, semen 
quality, duration of menstrual cycle
Nonsmoking women had no risk of reduced fecundability 
with total caffeine intake >700 mg/day 
FOR: 0.63 (95% Ci 0.25; 1.60) or caffeine intake from coffee 
>300 mg/day 
FOR: 0.87 (95% Ci 0.32; 2.37)
Among smokers, a total intake of caffeine 0–299 mg/day and 
a caffeine intake from coffee >300 mg/day were associated 
with reduced fecundability (FOR: 0.55 [95% Ci 0.32; 0.98] 
and FOR: 0.34 [95% Ci 0.12; 0.98], respectively) 
5
Pollack et al, 
201029
US Cohort N=66 American pregnancy planners 
Cases: 14
Multiple Yes Yes Age, average alcohol consumption and cigarette 
consumption per standardized 28-day cycle, and 
prior history of SAB
No risk of longer TTP with total caffeine intake (RR: 1.00 
[95% Ci 0.99; 1.01])
7
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Consumption of coffee or caffeine and fecundity and fertility
Table 1 Characteristics and results of publications on coffee/caffeine and fecundity endpoints
Author and 
year
Country Design Study groups
included in the analyses
Source of 
caffeine
Controls for 
maternal age
Controls 
for other 
important 
covariates
Confounding factors Main results Total NOS 
score
wilcox et al, 
198815
US Cohort N=104 volunteering healthy women who did not 
become pregnant in the first 3 months of trying to 
conceive
Multiple Yes Yes Age, frequency of intercourse, age at menarche, 
woman’s prenatal exposure to mother’s smoking. 
Subanalysis resticted to non-smokers 
women with a caffeine intake had a decreased fecundability
FOR: 0.51 (95% Ci 0.35; 0.75)
6
Christianson et al, 
198913
US Cohort N=6,303 pregnant women Coffee No Yes Ethnicity, parity, smoking women with a coffee intake of >7 cups/day had an increased 
risk of experiencing difficulties in becoming pregnant 
RR: 1.96*
4
Olsen, 19919 Denmark Cohort N=5,309 non-smoking pregnant Danish women who 
had reached their 3rd trimester
Cases: 523
Multiple Yes Yes Main analysis – data stratified on smoking status.
Adjusted for number of pregnancies, father’s age, 
mother’s and father’s alcohol drinking habits, shift 
work, mother’s education, mother’s and father’s 
smoking habits
Among nonsmokers, there was no association between 
coffee/tea intake >8 cups/day and TTP >6 or TTP >12 
months 
OR: 0.92 (95% Ci 0.71; 1.19) and OR: 0.98 (95% Ci 0.70; 1.37) 
Among smokers, an intake of >8 cups/day was associated 
with TTP >12 months
OR: 1.35 (95% Ci 1.02; 1.48)
6
Florack et al, 
199417
The 
Netherlands
Cohort N=259
Dutch women planning a pregnancy within a year, 
hospital workers 
Coffee No No Main analysis = crude analysis.
Subanalysis: controling for smoking and partners 
behavioral risk factors
women with a caffeine intake of 400–700 mg/day had an 
increased fecundability 
FOR: 2.10 (95% Ci 1.20; 3.70)
7
Alderete et al, 
199510
US Cohort N=787
Primigravidas and married American women 
Coffee Yes Yes Stratification by smoking status.
Adjusted for age, race, BMi, education, prior use of 
contraceptive pills, alcohol consumption, husband’s 
smoking habits, income, whether pregnancy was 
planned, abnormal reproductive conditions, immune 
and endocrine disorders
Nonsmoking women with a coffee intake >3 cups/day had no 
increased risk of TTP >3 months (187 cases)
OR: 1.10 (95% Ci 0.70; 1.80)
TTP >6 months (104 cases)
OR: 1.00 (95% Ci 0.60; 1.80) or TTP >12 months (56 cases)
OR: 1.00 (95% Ci 0.50; 1.70)
7
Bolúmar et al, 
19977 
Spain Cohort N=3,146
European women in the fertile age, planning their first 
pregnancy 
Multiple Yes Yes Age, parity, smoking, alcohol consumption, 
frequency of intercourse, educational level, working 
status, use of oral contraceptives, and country
Women with a caffeine intake during the first pregnancy of 
>500 mg/day had an increased risk of TTP >9.5 months
OR: 1.45 (95% Ci 1.03; 2.04)
No association between total caffeine intake >500 mg/day or 
coffee intake >5 cups/day and TTP >9.5 months (N=3.053)
OR: 1.32 (95% Ci 0.94; 1.86) and OR: 1.26 (95% Ci 0.91; 
1.74) during the most recent waiting time 
6
Caan et al, 199816 US Cohort N=187 volunteering American women, pregnancy 
planners who had been trying for 3 months or less to 
conceive
in total 737 cycles; 115 pregnant cycles and 622 non-
pregnant cycles 
Multiple/
coffee
Yes Yes Age, BMi, gravidity, frequency of intercourse, 
smoking, and alcoholic beverage
No risk of reduced fecundability with total caffeine intake 
>106.8 mg/day 
OR: 1.09 (95% Ci 0.63; 1.89)
or coffee intake >1 cup/day 
OR: 0.77 (95% Ci 0.43; 1.37)
6
Hakim et al, 
199819
US Cohort N=98 volunteering American women in the 
reproductive age, employed at two semiconductor 
plants
No. of conceptions: 90 
No. of menstrual cycles: 536 
Coffee Yes Yes Participants’ age, number of occurrences of sexual 
intercourse in each month, alcohol consumption.
The analysis was restricted to nonsmoking women
Nonsmoking women had no risk of reduced fecundability 
with caffeine intake >300 mg/day 
OR: 0.83 (95% Ci 0.34; 2.01)
7
Jensen et al, 
199814
Denmark Cohort N=423 volunteering Danish couples, nulliparous and 
pregnancy planners with 1,596 cycles 
Multiple/
coffee
No Yes Stratification by smoking.
Total caffeine adjusted for female BMi, alcohol 
intake, deseases of the reproductive organs, semen 
quality, duration of menstrual cycle
Nonsmoking women had no risk of reduced fecundability 
with total caffeine intake >700 mg/day 
FOR: 0.63 (95% Ci 0.25; 1.60) or caffeine intake from coffee 
>300 mg/day 
FOR: 0.87 (95% Ci 0.32; 2.37)
Among smokers, a total intake of caffeine 0–299 mg/day and 
a caffeine intake from coffee >300 mg/day were associated 
with reduced fecundability (FOR: 0.55 [95% Ci 0.32; 0.98] 
and FOR: 0.34 [95% Ci 0.12; 0.98], respectively) 
5
Pollack et al, 
201029
US Cohort N=66 American pregnancy planners 
Cases: 14
Multiple Yes Yes Age, average alcohol consumption and cigarette 
consumption per standardized 28-day cycle, and 
prior history of SAB
No risk of longer TTP with total caffeine intake (RR: 1.00 
[95% Ci 0.99; 1.01])
7
(Continued)
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Lyngsø et al
Author and 
year
Country Design Study groups
included in the analyses
Source of 
caffeine
Controls for 
maternal age
Controls 
for other 
important 
covariates
Confounding factors Main results Total NOS 
score
Taylor et al, 
201130
US Cohort N=470 American women who were sexually active and 
with no history of infertility
Multiple Yes Yes Age, trying to get pregnant, frequency of 
unprotected intercourse, BMi, average alcohol 
intake, smoking
No risk of reduced fecundability among women with a 
caffeine intake >300 mg/day (FOR: 0.89 [95% Ci 0.58; 1.38])
6
Hatch et al, 
201250
US Cohort N=2,484 Danish women, planning a pregnancy who had 
not been trying to conceive for >6 cycles at study entry
No. of pregnancies: 2,484
Cycles at risk: 15,225
Multiple/
coffee
Yes Yes Age, partner’s age, BMi, pack-years of smoking, 
number of alcoholic beverages consumed per week, 
physical activity (METs/week), and frequency of 
intercourse
(also adjusted for tea and cola in analyses concerning 
coffee)
No risk of reduced fecundability among women with a 
caffeine intake >300 mg/day (FOR: 1.06 [95% Ci 0.92; 1.23]) 
or coffee intake >3 cups/day (FOR: 1.01 [95% Ci 0.80; 1.27])
6
Notes: *No 95% Ci provided.
Abbreviations: 95% CI, 95% confidence interval; FOR, fecundability odds ratio; NOS, Newcastle–Ottawa scale; TTP, time to pregnancy; SAB, spontaneous abortion;  
BMi, body mass index.
Table 1 (Continued)
Table 2 Characteristics and results of publications on coffee/caffeine and spontaneous abortion (SAB)
Author and year Country Design Study groups included in the analyses Source of 
caffeine 
Controls for 
maternal age
Controls for 
other important 
covariates
Confounding factors Main results Total NOS 
score
Srisuphan and 
Bracken, 198634
US Cohort N=2,188 pregnant American women attending 
care at 29 private hospitals
Cases: 345
Multiple Yes No Gestational age at the interview, maternal 
age, prior gynecologic surgery, member of 
Jewish religion, SAB in last pregnancy
women consuming ≥151 mg caffeine/day had an increased 
risk of SAB 
RR: 1.73*
6
Axelsson and 
Rylander, 198931
Sweden Cohort N=654 Swedish shift-working women, including 
970 pregnancies
Coffee Yes No Age women with a coffee intake of >3 cups/day had an 
increased risk of miscarriage 
RR: 1.56 (95% Ci 1.06; 2.30)
5
wilcox et al, 199066 US Cohort N=104 healthy volunteering American women, 
who did not become pregnant in the first 3 
months of trying to conceive with 171 pregnancies
Cases: 43
Multiple Yes No Age No increased risk of early pregnancy loss with caffeine 
consumption >3,500 mg/month
RR: 2.40 (95% Ci 0.80; 7.00)
6
Fenster et al, 199151 US Case–
control
N=1,891 
Cases: 607 American women with SAB within the 
first 20 weeks of gestation
Controls: 1,284 women, frequency matched by 
last menstrual period and hospital, selected two 
per case from county live births
Multiple Yes Yes Age, race marital status, insurance coverage, 
cigarette and alcohol consumption, previous 
spontaneous abortions and previous 
therapeutic abortions
No increased risk of SAB with total caffeine intake 
>300 mg/day
OR: 1.22 (95% Ci 0.80; 1.87)
Among heavy users, nausea modified the risk of SAB 
OR: 2.10 (95% Ci 1.20; 3.70)
7
Kline et al, 199160 US Case–
control
N=2,441
Cases: 1,135 American women with SAB within 
the first 28 weeks of gestation
Controls: 1,306 pregnant women, matched by age 
and payment group
Multiple Yes No Adjusted for maternal age in the article (not 
able to include this in the meta-analysis, 
using crude estimates)
women with a perifertilization caffeine intake of 
28–124 mg/day had a decreased risk of SAB OR: 0.66 (95% 
Ci 0.52; 0.83)
women with a caffeine intake of 225–1,308 mg/day 
during pregnancy had an increased risk of SAB OR: 1.71 
(95% Ci 1.29; 2.26)
6
Parazzini et al, 199136 italy Case–
control
N=260
Cases: 94 italian women with two or more 
unexplained miscarriages and no full-term pregnancy
Controls: 176 women with normal delivery
Coffee Yes No Age (adjustment for alcohol was not done in 
the presented analysis)
No significant increased risk of SAB with coffee intake
OR: 1.40 (95% Ci 0.70; 2.60)
6
Armstrong et al, 
199253
US Cohort N=35,848 American women with previous 
pregnancy ending in either delivery or SAB
Cases: 7,606
Coffee Yes Yes Maternal age (at pregnancy outcome), 
pregnancy history, educational level, ethnic 
group, employment during pregnancy, 
cigarettes, alcohol
women with a coffee intake of 5–9 cups/day had an 
increased risk of SAB 
OR: 1.17 (95% Ci i.03; 1.32)
6
infante-Rivard et al, 
199361
Canada Case–
control
N=1,323
Cases: 331 Canadian women admitted for fetal 
loss
Controls: N=992 pregnant women expected 
to deliver at the same hospital, matched 3:1 on 
periods of pregnancy
Coffee Yes Yes Period of pregnancy, age, educational level, 
smoking and alcohol use during pregnancy, 
uterine abnormality, and work schedule
women with a pre-pregnancy caffeine intake >321 mg/day 
had an increased risk of SAB 
OR: 1.85 (95% Ci i.18; 2.89)
women with a caffeine intake of >321 mg/day during 
pregnancy had an increased risk of SAB OR: 2.62 
(95% Ci i.38; 5.01)
7
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Consumption of coffee or caffeine and fecundity and fertility
Author and 
year
Country Design Study groups
included in the analyses
Source of 
caffeine
Controls for 
maternal age
Controls 
for other 
important 
covariates
Confounding factors Main results Total NOS 
score
Taylor et al, 
201130
US Cohort N=470 American women who were sexually active and 
with no history of infertility
Multiple Yes Yes Age, trying to get pregnant, frequency of 
unprotected intercourse, BMi, average alcohol 
intake, smoking
No risk of reduced fecundability among women with a 
caffeine intake >300 mg/day (FOR: 0.89 [95% Ci 0.58; 1.38])
6
Hatch et al, 
201250
US Cohort N=2,484 Danish women, planning a pregnancy who had 
not been trying to conceive for >6 cycles at study entry
No. of pregnancies: 2,484
Cycles at risk: 15,225
Multiple/
coffee
Yes Yes Age, partner’s age, BMi, pack-years of smoking, 
number of alcoholic beverages consumed per week, 
physical activity (METs/week), and frequency of 
intercourse
(also adjusted for tea and cola in analyses concerning 
coffee)
No risk of reduced fecundability among women with a 
caffeine intake >300 mg/day (FOR: 1.06 [95% Ci 0.92; 1.23]) 
or coffee intake >3 cups/day (FOR: 1.01 [95% Ci 0.80; 1.27])
6
Notes: *No 95% Ci provided.
Abbreviations: 95% CI, 95% confidence interval; FOR, fecundability odds ratio; NOS, Newcastle–Ottawa scale; TTP, time to pregnancy; SAB, spontaneous abortion;  
BMi, body mass index.
Table 2 Characteristics and results of publications on coffee/caffeine and spontaneous abortion (SAB)
Author and year Country Design Study groups included in the analyses Source of 
caffeine 
Controls for 
maternal age
Controls for 
other important 
covariates
Confounding factors Main results Total NOS 
score
Srisuphan and 
Bracken, 198634
US Cohort N=2,188 pregnant American women attending 
care at 29 private hospitals
Cases: 345
Multiple Yes No Gestational age at the interview, maternal 
age, prior gynecologic surgery, member of 
Jewish religion, SAB in last pregnancy
women consuming ≥151 mg caffeine/day had an increased 
risk of SAB 
RR: 1.73*
6
Axelsson and 
Rylander, 198931
Sweden Cohort N=654 Swedish shift-working women, including 
970 pregnancies
Coffee Yes No Age women with a coffee intake of >3 cups/day had an 
increased risk of miscarriage 
RR: 1.56 (95% Ci 1.06; 2.30)
5
wilcox et al, 199066 US Cohort N=104 healthy volunteering American women, 
who did not become pregnant in the first 3 
months of trying to conceive with 171 pregnancies
Cases: 43
Multiple Yes No Age No increased risk of early pregnancy loss with caffeine 
consumption >3,500 mg/month
RR: 2.40 (95% Ci 0.80; 7.00)
6
Fenster et al, 199151 US Case–
control
N=1,891 
Cases: 607 American women with SAB within the 
first 20 weeks of gestation
Controls: 1,284 women, frequency matched by 
last menstrual period and hospital, selected two 
per case from county live births
Multiple Yes Yes Age, race marital status, insurance coverage, 
cigarette and alcohol consumption, previous 
spontaneous abortions and previous 
therapeutic abortions
No increased risk of SAB with total caffeine intake 
>300 mg/day
OR: 1.22 (95% Ci 0.80; 1.87)
Among heavy users, nausea modified the risk of SAB 
OR: 2.10 (95% Ci 1.20; 3.70)
7
Kline et al, 199160 US Case–
control
N=2,441
Cases: 1,135 American women with SAB within 
the first 28 weeks of gestation
Controls: 1,306 pregnant women, matched by age 
and payment group
Multiple Yes No Adjusted for maternal age in the article (not 
able to include this in the meta-analysis, 
using crude estimates)
women with a perifertilization caffeine intake of 
28–124 mg/day had a decreased risk of SAB OR: 0.66 (95% 
Ci 0.52; 0.83)
women with a caffeine intake of 225–1,308 mg/day 
during pregnancy had an increased risk of SAB OR: 1.71 
(95% Ci 1.29; 2.26)
6
Parazzini et al, 199136 italy Case–
control
N=260
Cases: 94 italian women with two or more 
unexplained miscarriages and no full-term pregnancy
Controls: 176 women with normal delivery
Coffee Yes No Age (adjustment for alcohol was not done in 
the presented analysis)
No significant increased risk of SAB with coffee intake
OR: 1.40 (95% Ci 0.70; 2.60)
6
Armstrong et al, 
199253
US Cohort N=35,848 American women with previous 
pregnancy ending in either delivery or SAB
Cases: 7,606
Coffee Yes Yes Maternal age (at pregnancy outcome), 
pregnancy history, educational level, ethnic 
group, employment during pregnancy, 
cigarettes, alcohol
women with a coffee intake of 5–9 cups/day had an 
increased risk of SAB 
OR: 1.17 (95% Ci i.03; 1.32)
6
infante-Rivard et al, 
199361
Canada Case–
control
N=1,323
Cases: 331 Canadian women admitted for fetal 
loss
Controls: N=992 pregnant women expected 
to deliver at the same hospital, matched 3:1 on 
periods of pregnancy
Coffee Yes Yes Period of pregnancy, age, educational level, 
smoking and alcohol use during pregnancy, 
uterine abnormality, and work schedule
women with a pre-pregnancy caffeine intake >321 mg/day 
had an increased risk of SAB 
OR: 1.85 (95% Ci i.18; 2.89)
women with a caffeine intake of >321 mg/day during 
pregnancy had an increased risk of SAB OR: 2.62 
(95% Ci i.38; 5.01)
7
(Continued)
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Author and year Country Design Study groups included in the analyses Source of 
caffeine 
Controls for 
maternal age
Controls for 
other important 
covariates
Confounding factors Main results Total NOS 
score
Mills et al, 199362 US Cohort N=423 American pregnancy planners (24% 
enrolled no later than 21 days after conception)
Cases: 59
Multiple Yes Yes Smoking, maternal age, parity, prior SAB, 
alcohol use, maternal education, and income
No increased risk of SAB with caffeine intake 
OR: 1.15 (95% Ci 0.89; 1.49)
8
Dominguez-Rojas 
et al, 199454
Spain Cohort N=691 Spanish women who were primipara 
Cases: 169
Coffee Yes No Age, previous SAB, menarcheal age, and 
marital status
women with a caffeine intake of 141–280, 281–420, and 
>420 mg/day had an increased risk of SAB 
OR: 2.20 (95% Ci i.22; 3.96), OR: 4.81 (95% Ci 2.28; 
10.14), and OR: 15.43 (95% Ci 7.34; 32.43)
5
Lubna and Al-Ansary, 
199437
Saudi Arabia Case–
control 
N=452 
Cases: 226 Saudi women hospitalized for SAB 
within the first 4 weeks of gestation
Controls: 226 women admitted for normal 
delivery
Multiple No No No women with a caffeine intake of >150 mg/day had an 
increased risk of SAB RR: 1.90 (95% Ci 1.20; 3.00)
5
Dlugosz et al, 199655 US Cohort N=2,849 pregnant American women recruited 
from private clinics 
Cases: 135
Multiple/
coffee 
Yes Yes Maternal age, gestational age at the 
interview, cigarette smoking, and alcoholic 
beverage consumption
(also adjusted for tea and soda intake when 
reporting results on coffee intake)
women with a coffee intake of >3 cups/day had an 
increased risk of SAB 
OR: 2.63 (95% Ci 1.29; 5.34)
8
Zhang and Bracken, 
199667
US Cohort N=2,849 pregnant American women recruited 
from private clinics 
Cases: 135
Coffee No No No women consuming ≥3 cups of coffee/day during the first 
month of pregnancy had an increased risk of SAB 
RR: 2.45 (95% Ci 1.38; 4.35)
3
Agnesi et al, 199757 italy Case–
control
N=216
Cases: 108 italian women with clinically 
recognized SAB
Controls: 108 women admitted for normal 
delivery; matched by age, year, and residence 
Coffee Yes Yes Gravidity, previous abortions, level of 
education, smoking habits, consumption 
of alcohol, medicines and marital status, 
solvent exposure
women with a coffee intake had an increased risk of SAB
RR: 1.36 (95% Ci 1.06; 1.76)
6
Fenster et al, 199752 US Cohort N=5,142 pregnant American women enrolled 
from three private facilities
Cases: 498
Multiple Yes Yes Maternal age, pregnancy history, cigarette 
smoking, alcohol consumption, employment, 
race, gestational age at interview, marital 
and socioeconomic status (also adjusted for 
tea, soda, and decaffeinated coffee when 
analyzing caffeinated coffee)
No increased risk of SAB with a prepregnancy intake of 
total caffeine >300 mg/day before pregnancy 
OR: 1.25 (95% Ci 0.90; 1.73) or coffee >3 cups/day 
OR: 1.13 (95% Ci 080; 1.60)
During first trimester, there were no increased risk of SAB 
with total caffeine intake >300 mg/day 
OR: 1.29 (95% Ci 0.80; 2.06)
or coffee intake >3 cups/day 
OR: 0.84 (95% Ci 0.41; 1.68)
7
Parazzini et al, 199863 italy Case–
control 
N=2,325
Cases: 782 italian women admitted for SAB within 
the first 12 weeks of gestation
Controls: 1,543 women who gave birth at term 
(>37 weeks of gestation) 
Coffee Yes Yes Age, education, previous live births, and 
SAB, maternal alcohol consumption and 
smoking in the first trimester, nausea 
intensity in the first trimester of pregnancy
women with a coffee consumption of 2–3 and ≥4 cups/day 
before conception had an increased risk of SAB
OR: 1.34 (95% Ci 1.04; 1.73) and OR: 1.47 (95% Ci 1.07; 2.02) 
women with a coffee consumption of 2–3 and ≥4 cups/day 
during the first trimester had an increased risk of SAB
OR: 1.75 (95% Ci 1.23; 2.29) and OR: 3.98 (95% Ci 2.55; 6.21) 
8
Cnattingius et al, 
200032
Sweden Case–
control
N=1,515
Cases: 562 Swedish women admitted with SAB 
within 6–12 weeks of gestation
Controls: 953 pregnant women, frequency-
matched on weeks of gestation and area of 
residence 
Multiple Yes Yes Smoking status, age, number of previous 
pregnancies, history of SAB, consumption of 
alcohol during pregnancy (yes/no), presence 
or absence of nausea, vomiting, and fatigue
No increased risk of early SAB with total caffeine intake 
≥500 mg/day during pregnancy 
OR: 1.40 (95% Ci 0.90; 2.20)
when stratifying on smoking status, nonsmokers with a 
caffeine intake ≥500 mg/day had an increased risk of SAB
OR: 2.20 (95% Ci 1.30; 3.80)
No association was found among smokers
8
wen et al, 200168 US Cohort N=550 American women planning to become 
pregnant and who had not been trying for more 
than 3 months at enrolment
Cases: 70
Multiple No No No No increased risk for SAB with total caffeine intake of 
≥300 mg/day before pregnancy 
RR: 1.10 (95% Ci 0.50; 2.40) 
A tendency of increased risk for SAB with total caffeine 
intake ≥300 mg/day during first trimester
RR: 2.50 (95% Ci 1.00; 6.40)
3
Table 2 (Continued)
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Consumption of coffee or caffeine and fecundity and fertility
Author and year Country Design Study groups included in the analyses Source of 
caffeine 
Controls for 
maternal age
Controls for 
other important 
covariates
Confounding factors Main results Total NOS 
score
Mills et al, 199362 US Cohort N=423 American pregnancy planners (24% 
enrolled no later than 21 days after conception)
Cases: 59
Multiple Yes Yes Smoking, maternal age, parity, prior SAB, 
alcohol use, maternal education, and income
No increased risk of SAB with caffeine intake 
OR: 1.15 (95% Ci 0.89; 1.49)
8
Dominguez-Rojas 
et al, 199454
Spain Cohort N=691 Spanish women who were primipara 
Cases: 169
Coffee Yes No Age, previous SAB, menarcheal age, and 
marital status
women with a caffeine intake of 141–280, 281–420, and 
>420 mg/day had an increased risk of SAB 
OR: 2.20 (95% Ci i.22; 3.96), OR: 4.81 (95% Ci 2.28; 
10.14), and OR: 15.43 (95% Ci 7.34; 32.43)
5
Lubna and Al-Ansary, 
199437
Saudi Arabia Case–
control 
N=452 
Cases: 226 Saudi women hospitalized for SAB 
within the first 4 weeks of gestation
Controls: 226 women admitted for normal 
delivery
Multiple No No No women with a caffeine intake of >150 mg/day had an 
increased risk of SAB RR: 1.90 (95% Ci 1.20; 3.00)
5
Dlugosz et al, 199655 US Cohort N=2,849 pregnant American women recruited 
from private clinics 
Cases: 135
Multiple/
coffee 
Yes Yes Maternal age, gestational age at the 
interview, cigarette smoking, and alcoholic 
beverage consumption
(also adjusted for tea and soda intake when 
reporting results on coffee intake)
women with a coffee intake of >3 cups/day had an 
increased risk of SAB 
OR: 2.63 (95% Ci 1.29; 5.34)
8
Zhang and Bracken, 
199667
US Cohort N=2,849 pregnant American women recruited 
from private clinics 
Cases: 135
Coffee No No No women consuming ≥3 cups of coffee/day during the first 
month of pregnancy had an increased risk of SAB 
RR: 2.45 (95% Ci 1.38; 4.35)
3
Agnesi et al, 199757 italy Case–
control
N=216
Cases: 108 italian women with clinically 
recognized SAB
Controls: 108 women admitted for normal 
delivery; matched by age, year, and residence 
Coffee Yes Yes Gravidity, previous abortions, level of 
education, smoking habits, consumption 
of alcohol, medicines and marital status, 
solvent exposure
women with a coffee intake had an increased risk of SAB
RR: 1.36 (95% Ci 1.06; 1.76)
6
Fenster et al, 199752 US Cohort N=5,142 pregnant American women enrolled 
from three private facilities
Cases: 498
Multiple Yes Yes Maternal age, pregnancy history, cigarette 
smoking, alcohol consumption, employment, 
race, gestational age at interview, marital 
and socioeconomic status (also adjusted for 
tea, soda, and decaffeinated coffee when 
analyzing caffeinated coffee)
No increased risk of SAB with a prepregnancy intake of 
total caffeine >300 mg/day before pregnancy 
OR: 1.25 (95% Ci 0.90; 1.73) or coffee >3 cups/day 
OR: 1.13 (95% Ci 080; 1.60)
During first trimester, there were no increased risk of SAB 
with total caffeine intake >300 mg/day 
OR: 1.29 (95% Ci 0.80; 2.06)
or coffee intake >3 cups/day 
OR: 0.84 (95% Ci 0.41; 1.68)
7
Parazzini et al, 199863 italy Case–
control 
N=2,325
Cases: 782 italian women admitted for SAB within 
the first 12 weeks of gestation
Controls: 1,543 women who gave birth at term 
(>37 weeks of gestation) 
Coffee Yes Yes Age, education, previous live births, and 
SAB, maternal alcohol consumption and 
smoking in the first trimester, nausea 
intensity in the first trimester of pregnancy
women with a coffee consumption of 2–3 and ≥4 cups/day 
before conception had an increased risk of SAB
OR: 1.34 (95% Ci 1.04; 1.73) and OR: 1.47 (95% Ci 1.07; 2.02) 
women with a coffee consumption of 2–3 and ≥4 cups/day 
during the first trimester had an increased risk of SAB
OR: 1.75 (95% Ci 1.23; 2.29) and OR: 3.98 (95% Ci 2.55; 6.21) 
8
Cnattingius et al, 
200032
Sweden Case–
control
N=1,515
Cases: 562 Swedish women admitted with SAB 
within 6–12 weeks of gestation
Controls: 953 pregnant women, frequency-
matched on weeks of gestation and area of 
residence 
Multiple Yes Yes Smoking status, age, number of previous 
pregnancies, history of SAB, consumption of 
alcohol during pregnancy (yes/no), presence 
or absence of nausea, vomiting, and fatigue
No increased risk of early SAB with total caffeine intake 
≥500 mg/day during pregnancy 
OR: 1.40 (95% Ci 0.90; 2.20)
when stratifying on smoking status, nonsmokers with a 
caffeine intake ≥500 mg/day had an increased risk of SAB
OR: 2.20 (95% Ci 1.30; 3.80)
No association was found among smokers
8
wen et al, 200168 US Cohort N=550 American women planning to become 
pregnant and who had not been trying for more 
than 3 months at enrolment
Cases: 70
Multiple No No No No increased risk for SAB with total caffeine intake of 
≥300 mg/day before pregnancy 
RR: 1.10 (95% Ci 0.50; 2.40) 
A tendency of increased risk for SAB with total caffeine 
intake ≥300 mg/day during first trimester
RR: 2.50 (95% Ci 1.00; 6.40)
3
(Continued)
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Lyngsø et al
Author and year Country Design Study groups included in the analyses Source of 
caffeine 
Controls for 
maternal age
Controls for 
other important 
covariates
Confounding factors Main results Total NOS 
score
Giannelli et al, 200358 UK Case–
control
N=469
Cases: 159 nulliparous English women with a 
clinically recognized miscarriage
Controls: 310 nulliparous pregnant women, 
without a SAB in 1st and 2nd trimesters
Multiple Yes No Maternal age, nausea in pregnancy, and 
gestational age
women with a caffeine intake of 301–500 and >500 mg/day 
during pregnancy had an increased risk of miscarriage 
OR: 1.94 (95% Ci 1.04; 3.63) and OR: 2.18 (95% Ci 
1.08; 4.40). women with a coffee intake of 107–321 and 
>321 mg/day during pregnancy had an increased risk of 
miscarriage 
OR: 2.19 (95% Ci 1.31; 3.64) and OR: 2.31 (95% Ci 1.21; 4.41) 
6
Rasch, 200377 Denmark Case–
control 
N=1,459
Cases: 320 Danish women with an SAB in 
gestational week 6–16
Controls: 1,139 pregnant women with a live fetus 
at gestational week 6–16
Multiple Yes Yes Age, parity, occupation, cigarette smoking, 
and alcohol consumption
women with a caffeine intake of ≥375 mg/day had an 
increased risk of SAB
OR: 2.21 (95% Ci 1.53; 3.18)
8
Tolstrup et al, 200369 Denmark Case–
control
N=1,712
Cases: 303 Danish women who reported an SAB 
or registered with a diagnosis of SAB
Controls: 1,409 women reporting giving birth or 
being pregnant for >28 weeks
Multiple Yes Yes Maternal age, marital status, smoking, and 
alcohol intake
A tendency of increased risk for SAB with total caffeine 
intake of >900 mg/day
OR: 1.72 (95% Ci 1.00; 2.96)
No interaction between caffeine and smoking
6
Khoury et al, 200435 US Cohort N=191 pregnant American women with type 1 
diabetes planning a pregnancy or enrolled after 
conception
Cases: 23
Multiple Yes No Maternal age, years since diagnosis of 
diabetes, previous SAB, nephropathy and 
retinopathy, glycemic control, and cigarette 
smoking 
Women who consumed caffeine early in the first trimester 
had an increased risk of SAB 4.50 (95% Ci 1.20; 16.80) 
compared to women not consuming caffeine
4
Bech et al, 200521 Denmark Cohort N=86,282 pregnant Danish women recruited by 
their GP
Cases: 616
Coffee Yes Yes Age, parity, smoking, prepregnancy 
BMi, alcohol consumption, and socio-
occupational status
women with a coffee intake of ≥8 cups/day had an 
increased risk of fetal death (gestation length <140 days) 
HR: 1.48 (95% Ci 1.01; 2.17)
7
Sata et al, 200570 Japan Case–
control
N=205
Cases: 58 Japanese women with a history of 
recurrent pregnancy loss
Controls: 147 fertile women whose pregnancies 
ended in live births 
Multiple Yes No Age and smoking status during pregnancy No statistical significant increased risk of RPL with a 
caffeine intake of ≥300 mg/day during pregnancy when 
compared to women with a caffeine intake of 0–99 mg/day
OR: 1.82 (95% Ci 0.72; 4.58)
women with homozygous CYP1A2*1F alleles had an 
increased risk of RPL with a caffeine intake of ≥300 mg/day
OR: 5.23 (95% Ci 1.05; 25.90)
6
George et al, 200659 Sweden Case–
control
N=691
Cases: 108 Swedish women admitted with two or 
more consecutive miscarriages
Controls: 583 pregnant women with at least two 
pregnancies, frequency-matched on weeks of 
gestation and area of residence 
Multiple Yes Yes Maternal age, obstetric history, induced 
abortions, myoma, time to concieve, marital 
status, smoking, alcohol intake during 
pregnancy, amd plasma folate levels
No statistical significant increased risk of RPL with a 
caffeine intake of ≥300 mg/day during pregnancy 
OR: 1.80 (95% Ci 0.80; 2.90)
Nonsmokers had an increased risk of RPL with a caffeine 
intake of ≥300 mg/day
OR: 2.70 (95% Ci 1.10; 6.20)
8
Maconochie et al, 
200764
UK Case–
control
N=6,167
Cases: 546 English women whose most recent 
pregnancy had ended in first trimester miscarriage 
(<13 weeks of gestation) or who had a miscarriage 
since 1995
Controls: N=5,621 women whose most recent 
pregnancy progressed beyond 13 weeks of 
gestation
Multiple Yes No Year of conception, maternal age at 
conception, pregnancy order, history of 
miscarriage, history of live birth
(further adjusted for nausea in one analysis)
women consuming 301–500 and >500 mg caffeine/day had 
an increased risk of miscarriage 
OR: 1.51 (95% Ci 1.06; 2.17) and OR: 1.70 (95% Ci 1.19; 
2.43)
5
Savitz et al, 200871 US Cohort N=2,370 pregnant American women enrolled 
before 12 weeks of gestation and who had not 
been trying to conceive for >6 months
Cases: 258
Multiple/
coffee
Yes Yes Maternal age, race/etnicity, maternal 
education, marital status, alcohol use, 
vitamin use and symptoms of nausea, and 
vomiting during early pregnancy
No increased risk of SAB with a prepregnancy coffee 
intake of >696 mg/day OR: 0.90 (95% Ci 0.50; 1.50) or 
total caffeine intake of >513.2 mg/day 
OR: 0.80 (95% Ci 0.50; 1.20)
No increased risk of SAB with a coffee intake of 
>372.9 mg/day at the time of the telephone interview 
OR: 0.70 (95% Ci 0.30; 1.80) or total caffeine intake of 
>273.2 mg/day 
OR: 1.30 (95% Ci 0.90; 1.19)
8
Table 2 (Continued)
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Consumption of coffee or caffeine and fecundity and fertility
Author and year Country Design Study groups included in the analyses Source of 
caffeine 
Controls for 
maternal age
Controls for 
other important 
covariates
Confounding factors Main results Total NOS 
score
Giannelli et al, 200358 UK Case–
control
N=469
Cases: 159 nulliparous English women with a 
clinically recognized miscarriage
Controls: 310 nulliparous pregnant women, 
without a SAB in 1st and 2nd trimesters
Multiple Yes No Maternal age, nausea in pregnancy, and 
gestational age
women with a caffeine intake of 301–500 and >500 mg/day 
during pregnancy had an increased risk of miscarriage 
OR: 1.94 (95% Ci 1.04; 3.63) and OR: 2.18 (95% Ci 
1.08; 4.40). women with a coffee intake of 107–321 and 
>321 mg/day during pregnancy had an increased risk of 
miscarriage 
OR: 2.19 (95% Ci 1.31; 3.64) and OR: 2.31 (95% Ci 1.21; 4.41) 
6
Rasch, 200377 Denmark Case–
control 
N=1,459
Cases: 320 Danish women with an SAB in 
gestational week 6–16
Controls: 1,139 pregnant women with a live fetus 
at gestational week 6–16
Multiple Yes Yes Age, parity, occupation, cigarette smoking, 
and alcohol consumption
women with a caffeine intake of ≥375 mg/day had an 
increased risk of SAB
OR: 2.21 (95% Ci 1.53; 3.18)
8
Tolstrup et al, 200369 Denmark Case–
control
N=1,712
Cases: 303 Danish women who reported an SAB 
or registered with a diagnosis of SAB
Controls: 1,409 women reporting giving birth or 
being pregnant for >28 weeks
Multiple Yes Yes Maternal age, marital status, smoking, and 
alcohol intake
A tendency of increased risk for SAB with total caffeine 
intake of >900 mg/day
OR: 1.72 (95% Ci 1.00; 2.96)
No interaction between caffeine and smoking
6
Khoury et al, 200435 US Cohort N=191 pregnant American women with type 1 
diabetes planning a pregnancy or enrolled after 
conception
Cases: 23
Multiple Yes No Maternal age, years since diagnosis of 
diabetes, previous SAB, nephropathy and 
retinopathy, glycemic control, and cigarette 
smoking 
Women who consumed caffeine early in the first trimester 
had an increased risk of SAB 4.50 (95% Ci 1.20; 16.80) 
compared to women not consuming caffeine
4
Bech et al, 200521 Denmark Cohort N=86,282 pregnant Danish women recruited by 
their GP
Cases: 616
Coffee Yes Yes Age, parity, smoking, prepregnancy 
BMi, alcohol consumption, and socio-
occupational status
women with a coffee intake of ≥8 cups/day had an 
increased risk of fetal death (gestation length <140 days) 
HR: 1.48 (95% Ci 1.01; 2.17)
7
Sata et al, 200570 Japan Case–
control
N=205
Cases: 58 Japanese women with a history of 
recurrent pregnancy loss
Controls: 147 fertile women whose pregnancies 
ended in live births 
Multiple Yes No Age and smoking status during pregnancy No statistical significant increased risk of RPL with a 
caffeine intake of ≥300 mg/day during pregnancy when 
compared to women with a caffeine intake of 0–99 mg/day
OR: 1.82 (95% Ci 0.72; 4.58)
women with homozygous CYP1A2*1F alleles had an 
increased risk of RPL with a caffeine intake of ≥300 mg/day
OR: 5.23 (95% Ci 1.05; 25.90)
6
George et al, 200659 Sweden Case–
control
N=691
Cases: 108 Swedish women admitted with two or 
more consecutive miscarriages
Controls: 583 pregnant women with at least two 
pregnancies, frequency-matched on weeks of 
gestation and area of residence 
Multiple Yes Yes Maternal age, obstetric history, induced 
abortions, myoma, time to concieve, marital 
status, smoking, alcohol intake during 
pregnancy, amd plasma folate levels
No statistical significant increased risk of RPL with a 
caffeine intake of ≥300 mg/day during pregnancy 
OR: 1.80 (95% Ci 0.80; 2.90)
Nonsmokers had an increased risk of RPL with a caffeine 
intake of ≥300 mg/day
OR: 2.70 (95% Ci 1.10; 6.20)
8
Maconochie et al, 
200764
UK Case–
control
N=6,167
Cases: 546 English women whose most recent 
pregnancy had ended in first trimester miscarriage 
(<13 weeks of gestation) or who had a miscarriage 
since 1995
Controls: N=5,621 women whose most recent 
pregnancy progressed beyond 13 weeks of 
gestation
Multiple Yes No Year of conception, maternal age at 
conception, pregnancy order, history of 
miscarriage, history of live birth
(further adjusted for nausea in one analysis)
women consuming 301–500 and >500 mg caffeine/day had 
an increased risk of miscarriage 
OR: 1.51 (95% Ci 1.06; 2.17) and OR: 1.70 (95% Ci 1.19; 
2.43)
5
Savitz et al, 200871 US Cohort N=2,370 pregnant American women enrolled 
before 12 weeks of gestation and who had not 
been trying to conceive for >6 months
Cases: 258
Multiple/
coffee
Yes Yes Maternal age, race/etnicity, maternal 
education, marital status, alcohol use, 
vitamin use and symptoms of nausea, and 
vomiting during early pregnancy
No increased risk of SAB with a prepregnancy coffee 
intake of >696 mg/day OR: 0.90 (95% Ci 0.50; 1.50) or 
total caffeine intake of >513.2 mg/day 
OR: 0.80 (95% Ci 0.50; 1.20)
No increased risk of SAB with a coffee intake of 
>372.9 mg/day at the time of the telephone interview 
OR: 0.70 (95% Ci 0.30; 1.80) or total caffeine intake of 
>273.2 mg/day 
OR: 1.30 (95% Ci 0.90; 1.19)
8
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Author and year Country Design Study groups included in the analyses Source of 
caffeine 
Controls for 
maternal age
Controls for 
other important 
covariates
Confounding factors Main results Total NOS 
score
weng et al, 200872 US Cohort N=1,063 pregnant American women enrolled 
before 14 weeks of gestation 
Cases: 172 
Multiple/
coffee
Yes Yes Maternal age, race, education, household 
income, marital status, previous 
miscarriages, smoking, alcohol consumption, 
jacuzzi use, MF exposure, and nausea and 
vomiting
women consuming >200 mg caffeine/day had an increased 
risk of miscarriage 
HR: 2.23 (1.34; 3.69)
6
Agnesi et al, 201056 italy Case–
control
N=245
Cases: 123 italian women with a clinically 
recognized SAB
Controls: 122 women admitted for normal 
delivery, matched by age, year, and residence 
Coffee Yes No No A tendency toward an increased risk of SAB with a coffee 
intake of 4 cups/day
OR: 4.48 (0.44; 2.23)
5
Greenwood et al, 
201065
UK Cohort N=2,482 pregnant English women
Cases: 25 
Multiple/
coffee
Yes Yes Maternal age, parity, amount smoked 
(cotinine concentration) and alcohol intake 
(no change in results by further adjusting 
for nausea)
women with a caffeine intake of >300 mg/day had an 
increased risk of late miscarriage 
OR: 5.10 (1.60; 16.40)
8
Pollack et al, 201029 US Cohort N=67 American women planning a pregnancy 
within the next 5 years and who became pregnant 
Cases: 14
Coffee Yes Yes Age, average alcohol consumption, and 
cigarette consumption per standardized 
28-day cycle
women with an intake of caffeine did not have an 
increased risk of miscarriage
RR: 0.98 (0.96; 0.99)
6
Stefanidou et al, 
201133
italy Case–
control
N=312 
Cases: 52 italian women with sine causa recurrent 
miscarriages 
Controls: 260 women with healthy pregnancies
Multiple Yes Yes Maternal age at conception, cigarette 
smoking, alcohol consumption, maternal 
education nausea/vomiting
For each 100 mg increase in caffeine intake per day the 
risk of sine causa recurrent miscarriage increased 
OR: 2.72 (2.71; 2.73)
7
Hanh et al, 201573 Denmark Cohort N=5,132 Danish women planning a pregnancy, 
18-40 years
Cases: 732
Multiple/
Coffee 
Yes Yes Maternal age, physical activity, parity, BMi, 
vocational training/education, smoking, prior 
SAB, alcohol (preconception estimate)
Preconception caffeine consumption was not appreciably 
associated with SAB overall
Early pregnancy caffeine consumption was associated with 
a slightly increased risk of SAB HR: 1.48 (95% Ci 1.03; 
2.13) when comparing a caffeine intake of 200–299 mg/day 
with ≤100 mg/day
7
Abbreviations: RPL, recurrent pregnancy loss; NOS, Newcastle–Ottawa scale;  MF, magnetic fields; TTP, time to pregnancy; SAB, spontaneous abortion; BMI, body mass index;  
RR, relative risk; METS, estimated total metabolic equivalents; OR, odds ratio; HR, hazards ratio.
Table 3 Characteristics and results of publications on coffee/caffeine and MAR treatment
Author and year Country Design Study groups
included in the analyses
Source of 
caffeine
Controls for 
maternal age
Controls for 
other important 
covariates
Confounding factors Main results Total NOS-
score
Klonoff-Cohen et al, 
200274
US Cohort N=192 American women with primary or 
secondary infertility undergoing their first 
fresh, non-donor ivF, or GiFT cycle 
Cases: 40
Multiple Yes Yes Smoking, alcohol use, age, race, education, 
parity, type of infertility, type of procedure, 
number of attempts, number of embryos 
transferred
women with a caffeine intake of >2–50 mg/day during the 
week of the initial clinical visit had an increased risk of SAB 
OR: 9.50 (95% Ci 1.40; 62.00)
women with a caffeine intake of >2–50 or >50 mg/day during 
the week of the initial clinical visit had an increased risk of not 
achieving a live birth OR: 2.90 (95% Ci 1.10; 7.50) and OR: 
3.80 (95% Ci 1.40; 10.70), respectively)
7
Al-Saleh et al, 201075 Saudi Arabia Cohort N=474 Saudi Arabian women undergoing 
their first IVF treatment 
Cases: 184
Multiple/coffee Yes Yes women’s age, BMi, cause of infertility, 
family income, smoking status, use of 
herbal treatment, and health status
No association between the chance of achieving a pregnancy 
and a coffee intake of >10 cups/day OR: 0.77 (95% Ci 0.22; 2.74)
No association between the chance of achieving a pregnancy and 
serum-caffeine OR: 0.93 (95% Ci 0.65; 1.33)
7
Choi et al, 201176 US Cohort N=2,474 American women undergoing 
ivF treatment at three fertility clinics in 
Boston and contributing 4,716 ivF cycles 
Cases: 1,147 
Multiple Yes Yes Female age, BMi, clinic site, study 
enrollment period, female tobacco use, 
female alcohol use, primary infertility 
diagnosis
No association between female caffeine consumption and the 
live birth rate
women with a caffeine intake of 1–114 mg/day or >200 mg/day 
had no decreased risk of achieving a live birth OR: 1.00  
(95% Ci 0.83; 1.21) and OR: 1.07 (95% Ci 0.85; 1.34), respectively 
7
Abbreviations: GiFT,  gamete intra-fallopian transfer; NOS, Newcastle–Ottawa scale; ivF, in vitro fertilization; SAB, spontaneous abortion; BMi, body mass index; OR, 
odds ratio.
Table 2 (Continued)
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Author and year Country Design Study groups included in the analyses Source of 
caffeine 
Controls for 
maternal age
Controls for 
other important 
covariates
Confounding factors Main results Total NOS 
score
weng et al, 200872 US Cohort N=1,063 pregnant American women enrolled 
before 14 weeks of gestation 
Cases: 172 
Multiple/
coffee
Yes Yes Maternal age, race, education, household 
income, marital status, previous 
miscarriages, smoking, alcohol consumption, 
jacuzzi use, MF exposure, and nausea and 
vomiting
women consuming >200 mg caffeine/day had an increased 
risk of miscarriage 
HR: 2.23 (1.34; 3.69)
6
Agnesi et al, 201056 italy Case–
control
N=245
Cases: 123 italian women with a clinically 
recognized SAB
Controls: 122 women admitted for normal 
delivery, matched by age, year, and residence 
Coffee Yes No No A tendency toward an increased risk of SAB with a coffee 
intake of 4 cups/day
OR: 4.48 (0.44; 2.23)
5
Greenwood et al, 
201065
UK Cohort N=2,482 pregnant English women
Cases: 25 
Multiple/
coffee
Yes Yes Maternal age, parity, amount smoked 
(cotinine concentration) and alcohol intake 
(no change in results by further adjusting 
for nausea)
women with a caffeine intake of >300 mg/day had an 
increased risk of late miscarriage 
OR: 5.10 (1.60; 16.40)
8
Pollack et al, 201029 US Cohort N=67 American women planning a pregnancy 
within the next 5 years and who became pregnant 
Cases: 14
Coffee Yes Yes Age, average alcohol consumption, and 
cigarette consumption per standardized 
28-day cycle
women with an intake of caffeine did not have an 
increased risk of miscarriage
RR: 0.98 (0.96; 0.99)
6
Stefanidou et al, 
201133
italy Case–
control
N=312 
Cases: 52 italian women with sine causa recurrent 
miscarriages 
Controls: 260 women with healthy pregnancies
Multiple Yes Yes Maternal age at conception, cigarette 
smoking, alcohol consumption, maternal 
education nausea/vomiting
For each 100 mg increase in caffeine intake per day the 
risk of sine causa recurrent miscarriage increased 
OR: 2.72 (2.71; 2.73)
7
Hanh et al, 201573 Denmark Cohort N=5,132 Danish women planning a pregnancy, 
18-40 years
Cases: 732
Multiple/
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Yes Yes Maternal age, physical activity, parity, BMi, 
vocational training/education, smoking, prior 
SAB, alcohol (preconception estimate)
Preconception caffeine consumption was not appreciably 
associated with SAB overall
Early pregnancy caffeine consumption was associated with 
a slightly increased risk of SAB HR: 1.48 (95% Ci 1.03; 
2.13) when comparing a caffeine intake of 200–299 mg/day 
with ≤100 mg/day
7
Abbreviations: RPL, recurrent pregnancy loss; NOS, Newcastle–Ottawa scale;  MF, magnetic fields; TTP, time to pregnancy; SAB, spontaneous abortion; BMI, body mass index;  
RR, relative risk; METS, estimated total metabolic equivalents; OR, odds ratio; HR, hazards ratio.
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Controls for 
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Controls for 
other important 
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US Cohort N=192 American women with primary or 
secondary infertility undergoing their first 
fresh, non-donor ivF, or GiFT cycle 
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Multiple Yes Yes Smoking, alcohol use, age, race, education, 
parity, type of infertility, type of procedure, 
number of attempts, number of embryos 
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week of the initial clinical visit had an increased risk of SAB 
OR: 9.50 (95% Ci 1.40; 62.00)
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the week of the initial clinical visit had an increased risk of not 
achieving a live birth OR: 2.90 (95% Ci 1.10; 7.50) and OR: 
3.80 (95% Ci 1.40; 10.70), respectively)
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Al-Saleh et al, 201075 Saudi Arabia Cohort N=474 Saudi Arabian women undergoing 
their first IVF treatment 
Cases: 184
Multiple/coffee Yes Yes women’s age, BMi, cause of infertility, 
family income, smoking status, use of 
herbal treatment, and health status
No association between the chance of achieving a pregnancy 
and a coffee intake of >10 cups/day OR: 0.77 (95% Ci 0.22; 2.74)
No association between the chance of achieving a pregnancy and 
serum-caffeine OR: 0.93 (95% Ci 0.65; 1.33)
7
Choi et al, 201176 US Cohort N=2,474 American women undergoing 
ivF treatment at three fertility clinics in 
Boston and contributing 4,716 ivF cycles 
Cases: 1,147 
Multiple Yes Yes Female age, BMi, clinic site, study 
enrollment period, female tobacco use, 
female alcohol use, primary infertility 
diagnosis
No association between female caffeine consumption and the 
live birth rate
women with a caffeine intake of 1–114 mg/day or >200 mg/day 
had no decreased risk of achieving a live birth OR: 1.00  
(95% Ci 0.83; 1.21) and OR: 1.07 (95% Ci 0.85; 1.34), respectively 
7
Abbreviations: GiFT,  gamete intra-fallopian transfer; NOS, Newcastle–Ottawa scale; ivF, in vitro fertilization; SAB, spontaneous abortion; BMi, body mass index; OR, 
odds ratio.
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100 mg caffeine/day, 1.37 (95% CI: 1.19; 1.57) for 300 mg 
caffeine/day, and 2.32 (95% CI: 1.62; 3.31) for 600 mg caf-
feine/day. There was evidence of significant between-study 
heterogeneity (I2=73,7%; p<0.0001), and Egger’s regres-
sion test provided evidence of substantial publication bias 
(p<0.0001; Table 2). 
We stratified the SAB analyses on type of consump-
tion, adjustment status, study quality, and study design. The 
analyses revealed that the associations were similar between 
studies reporting caffeine and coffee consumption (p for 
heterogeneity=0.87). Also, the associations were similar 
across strata according to adjustment status (ie, studies with 
adjusted results compared to unadjusted results) (p for hetero-
geneity=0.44) and according to study quality (ie, comparing 
studies with NOS ≥7 with those of NOS <7) (p for hetero-
geneity=0.22). We found weak evidence of a difference by 
study design with the associations being more pronounced in 
cohort studies than in case–control studies (p for heterogene-
ity=0.04). In a sensitivity analysis, changing the conversion 
factor of caffeine contained in one cup of coffee from 100 
mg to 150 mg did not substantially change the results.
Studies not eligible for meta-analysis 
Five other studies, not included in the meta-analysis, have inves-
tigated a possible association between coffee/caffeine consump-
tion and SAB with consistent findings in line with our results. 
A Swedish cohort study including 654 women31 reported an 
increased risk of SAB with a daily coffee consumption greater 
than three cups, while a case–control study among 452 Saudi-
Arabian women37 showed an association at caffeine consumption 
levels >150 mg/day. Also, the association of an increased risk of 
SAB with caffeine consumption was found among a selected 
group of 191 American women with type-1 diabetes.35 In an Ital-
ian case–control study including 312 women,33 a dose–response 
association was reported between caffeine intake and risk of 
recurrent SAB. Also, Parazzini et al36 found an association 
with any coffee consumption among women with recurrent 
pregnancy loss in a case–control study including 260 women; 
however, results were not statistically significant.
MAR treatment
Only two cohort studies provided sufficient data on live birth 
rate among couples undergoing in vitro fertilization (IVF) 
Figure 2 Dose–response association between caffeine consumption and odds ratio of fecundability (A), relative risk of time to pregnancy >6 months (B) and >12 months 
(C), spontaneous abortion (D), and live birth rate among couples receiving MAR treatment (E) compared to 0 mg consumption as reference. Odds ratios/relative risks are 
plotted on the log scale with 95% confidence intervals for the spline model. Tick marks on the x-axis represent category medians of exposure from the included studies.
Abbreviations: MAR, medically assisted reproduction.
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treatment74,76 to be included in the dose–response meta-
analysis. The results did not indicate an association between 
caffeine intake and the live birth rate among women in fertil-
ity treatment (p= 0.94; Figure 2E). The pooled relative risks 
for achieving a live birth were 0.99 (95% CI: 0.89; 1.10) for 
100 mg caffeine/day and 1.00 (95% CI: 0.80; 1.24) for 300 
mg caffeine/day, compared with no caffeine intake. 
Study not eligible for meta-analysis 
Only one study by Al-Saleh et al75 reported on the pregnancy 
rate among couples undergoing fertility treatment. The study 
showed no association between coffee/tea consumption or 
serum caffeine concentration and the success rate of preg-
nancy among 619 Saudi-Arabian women undergoing their 
first IVF-treatment cycle. However, the number of eggs was 
lower at higher levels of serum caffeine.
Discussion
This systematic review and meta-analysis showed no clear 
association between exposure to coffee/caffeine and natural 
fertility as measured by FOR or waiting TTP. However, due 
to the limited number of studies included, no firm conclu-
sions can be drawn for these endpoints. Our pooled results 
indicate that coffee/caffeine consumption is associated with 
a significantly increased risk of SAB, as expected from previ-
ous reviews and meta-analyses.23,78,79 Further, in addition to 
previous studies, we intended to capture nonlinear associa-
tions using novel statistical methods but found no evidence 
of a “threshold effect”. With regard to the potential effect of 
coffee or caffeine consumption on the outcomes of fertility 
treatment, our sparse results on MAR treatment as measured 
by the pregnancy and live birth rate in connection with IVF 
treatment did not show an association. Yet, the data available 
enable us to conclude little about the potential dose–response 
relationship. 
Various hypotheses exist concerning the possible mecha-
nisms of the potential effect of caffeine on different fecundity 
and pregnancy outcomes, but the eventual mechanisms are 
still unclear. Within the human body, caffeine acts as a non-
selective adenosine antagonist;80 it increases the intracellular 
concentration of cyclic AMP81 and alters the blood levels 
of catecholamines.82 Coffee and caffeine consumption may 
affect the reproductive health by affecting endogenous hor-
mone levels through changes in ovarian function or alterations 
in hormone metabolism: numerous studies have reported 
an inverse association between coffee/caffeine intake and 
levels of free estradiol83–86 in line with the increased levels 
of sex hormone–binding globulin reported by others.87–89 
However, contradicting results of increased levels76,90 or no 
effects on estradiol levels are also reported.87,88,91,92 Caffeine 
and estradiol are both metabolized by the hepatic enzyme 
CYP1A293,94, so a possible pathway for caffeine to interfere 
with estradiol levels is through a common metabolism. Also, 
besides caffeine, coffee contains numerous other bioactive 
substances including lignans and isoflavonoids, both belong-
ing to the phytoestrogen family with great affinity for the 
estrogen receptor.4 As a consequence, changes in hormonal 
levels might impact on the menstrual cycle, and a daily caf-
feine consumption >300 mg has been associated with shorter 
but not with longer menstrual cycle length.95 Moreover, caf-
feine intake was not associated with the number of oocytes 
retrieved, the fertilization rate, or implantation rate among 
women receiving fertility treatment.76 The conflicting results 
on coffee’s potential effect on the hormonal pathways are in 
line with our results suggesting no clear association with 
fecundity endpoints. In pregnant women, caffeine readily 
crosses the placental barrier and as a result is distributed to 
all fetal tissue, making the fetus exposed to the same caffeine 
levels as the mother.96 Also, coffee intake has been associ-
ated with decreased levels of both estrogen and hCG,97 and 
caffeine consumption during pregnancy is shown to increase 
levels of catecholamines and cyclic adenosine monophos-
phate that might impact on placental blood flow.98–100 Indeed, 
these pathways could have an influence on the increased risk 
of SAB as observed in this meta-analysis. 
This review and meta-analysis has several strengths, 
including the broader investigation of possible routes of 
interfering with the ability to conceive and carry a pregnancy 
to term. Another strength is the dose–response analysis, 
allowing us to include all information on exposure outcome 
by including information on intermediate categories, thus 
making the analysis more effective than the traditional highest 
versus lowest approach. Using this method, we were able to 
provide a detailed and more flexible description of the risk 
of outcome throughout the observed range of exposure. For 
the SAB analysis, we were able to include a relatively large 
number of studies providing higher statistical power and 
allowing us to perform stratified analyses. Hence, we were 
able to consider potential sources of heterogeneity, including 
taking into account the varying quality of the included studies.
However, this systematic review and dose–response 
meta-analysis also has several potential limitations. Though 
a majority of the included studies adjusted for potential 
confounders, the presence of residual or unmeasured con-
founding cannot be excluded due to the observational nature 
of the included studies. We observed marked between-study 
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heterogeneity, which can be caused by methodological or 
actual differences between the included studies. Conse-
quently, data on SAB were analyzed using a random-effects 
model. In addition, possible sources of heterogeneity in SAB 
studies were addressed in stratified analysis, and only study 
design was found of significance. 
Based on the current knowledge, we chose alcohol instead 
of smoking to be the second most important factor to adjust 
for in studies reporting on SAB. However, had smoking 
been selected instead, the NOS would have differed only by 
one point in three of the 33 evaluated studies as 18 adjusted 
for both alcohol consumption and smoking, while 12 did 
not adjust for either of the two. A priori, we determined the 
threshold for depicting a high-quality study as an NOS ≥7. 
However, changing the threshold in a sensitivity analysis to 
NOS ≥8 did not noticeably alter the association in the two 
strata (p for heterogeneity=0.28). 
We found evidence of publication bias for studies report-
ing on SAB, indicating that small studies not reporting any 
association are less likely to be published. Thus, results from 
SAB analysis should be interpreted bearing this in mind. Due 
to the limited number of studies reporting sufficient data on 
fecundity or MAR endpoints, assessment of publication bias 
for these could not be done. 
As data on caffeine were self-reported and obtained by 
various questionnaires or interview, exposure misclassifi-
cation of coffee/caffeine intake is unavoidable. Especially 
studies with retrospectively collected exposure data are prone 
to recall bias. Further, due to the numerous types of question-
naires used to assess exposure, the accuracy and data quality 
are expected to differ accordingly. 
Yet, validation studies support that coffee consumption 
can be assessed with fairly high validity.101 Due to the vari-
ous sources of exposure, it is difficult to estimate the total 
caffeine consumption accurately. Further, coffee contains a 
series of different chemical substances, making it difficult 
to segregate potential biological effects from caffeine from 
those of other bioactive compounds. Also, content of the dif-
ferent substances in coffee varies by type of bean, brewing 
method, and cup size.102 Thus, a possible association might 
be caused by other compounds or by a cocktail effect due 
to simultaneous exposure to multiple bioactive substances. 
However, most studies have focused on exposure to caffeine 
and thus only to some extent on exposure to coffee. In general, 
exposure assessment was reported as the average daily intake, 
and consequently we were not able to take the consumption 
patterns of coffee/caffeine into account. Also, different con-
version factors were used in studies when translating coffee 
consumption into caffeine. In the meta-analysis, we tried to 
quantify the amount of caffeine intake when exposure was 
only reported as cups of coffee, but by doing so, we were 
unable to integrate the pronounced variation in caffeine 
content by different types of coffee consumed. However, 
changing the conversion factor up to 150 mg caffeine per 
cup of coffee in a sensitivity analyses did not change the 
risk of SAB markedly. 
The actual level of caffeine exposure might vary greatly 
due to individual differences in the CYP1A2 gene  activity.70,103 
Hence, polymorphism of CYP1A2 has been linked to both 
variability in the clearance rate of caffeine104 and variability 
in serum estradiol concentrations.105 As a consequence, the 
half-life of caffeine varies between 1.5 hours for fast metabo-
lizers and up to 10 hours for slow metabolizers,4 making it 
difficult to settle on a relevant window of exposure.
In the context of SAB, reverse causation has to be con-
sidered; a viable pregnancy might produce more pronounced 
pregnancy symptoms, resulting in greater aversion to coffee and 
thus a decreased caffeine intake. However, a clinically verified 
SAB may be diagnosed weeks after the actual fetal demise and 
thus the yet unrecognized pregnancy loss might be the cause of 
an increased caffeine consumption rather than the opposite – an 
increased consumption causing adverse reproductive outcomes. 
In contrast to previous meta-analyses78,79 that presented pooled 
endpoints of SAB with still birth/fetal death, we only included 
SAB, as the underlying etiology indeed are different. 
Six cohort studies out of the included 32 studies on SAB 
verified the presence of a pregnancy at the time of reporting 
exposure, thereby reducing the risk of reversed causation. 
Among these studies, an association between caffeine intake 
and SAB was indicated, albeit only statistically significant 
in three studies. 
Due to the great differences in caffeine metabolism, future 
studies may benefit from actually evaluating circulating caf-
feine levels or its metabolites (eg, serum paraxanthine, the 
main metabolite) in linkage with genotyping to heighten the 
information of the actual exposure level. Thus, future studies 
could consider Mendelian randomization. Also, to possibly 
segregate effects of caffeine from those of other bioactive 
substances in coffee, future studies could consider evaluating 
the consumption of decaffeinated coffee. 
Conclusion
In conclusion, results from this dose–response meta-analysis 
support the evidence of an association between coffee/caf-
feine intake and the risk of SAB. However, results from the 
SAB analyses have to be interpreted with caution due to 
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the significant heterogeneity and risk of bias detected, not 
least the considerable risk of publication bias. As coffee is 
the main source of caffeine consumption, it is still unclear 
whether the association between coffee/caffeine consumption 
and SAB is related to the potential harmful effects of caf-
feine or to some of the other bioactive components of coffee. 
Viewing the reproductive capacity in a broader perspective, 
there seems to be little, if any, association between coffee/
caffeine consumption and fecundity. Even so, there is still a 
need for further studies to investigate the fecundity and MAR 
endpoints on a larger scale than previously done, using better 
study designs and including improved reporting combined 
with relevant adjustment strategies. 
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